We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

94 hedge funds and large institutions have $482M invested in Applied Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,040% more call options, than puts

Call options by funds: $4.97M | Put options by funds: $436K

41% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 22

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

6% more funds holding

Funds holding: 8994 (+5)

1.64% more ownership

Funds ownership: 88.74%90.38% (+1.6%)

25% less capital invested

Capital invested by funds: $639M → $482M (-$157M)

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

Holders
94
Holders Change
+5
Holders Change %
+5.62%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
30
Increased
31
Reduced
22
Closed
24
Calls
$4.97M
Puts
$436K
Net Calls
+$4.53M
Net Calls Change
-$39.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$47.7M -$1.66M -351,400 -3%
VA
2
VR Adviser
New York
$44.6M +$2.21M +467,871 +5%
PA
3
Perceptive Advisors
New York
$37.4M
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$35.5M +$5.84M +1,233,563 +19%
BlackRock
5
BlackRock
New York
$30.7M +$26.4M +5,580,510 +564%
PBM
6
Propel Bio Management
California
$30.7M +$2.16M +455,952 +7%
KCM
7
Knoll Capital Management
Florida
$26M
VPC
8
Vestal Point Capital
New York
$25.4M +$1.51M +320,000 +6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$24.9M +$10.9M +2,312,170 +77%
Morgan Stanley
10
Morgan Stanley
New York
$16.4M +$1.54M +325,685 +10%
SAM
11
Simplify Asset Management
Nevada
$13.2M
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$13M +$592K +125,000 +5%
Deutsche Bank
13
Deutsche Bank
Germany
$10.9M +$8.15M +1,721,256 +277%
TCM
14
Tang Capital Management
California
$10.9M +$473K +100,000 +4%
FLSM
15
Frazier Life Sciences Management
California
$10.7M +$1.58M +333,278 +17%
SC
16
Stempoint Capital
New York
$10.3M +$919K +194,304 +10%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$9.8M +$7.07M +1,494,387 +247%
Alyeska Investment Group
18
Alyeska Investment Group
Illinois
$9.18M +$2.47M +522,720 +36%
OM
19
Opaleye Management
Massachusetts
$7.85M -$426K -90,000 -5%
State Street
20
State Street
Massachusetts
$7.73M +$6.86M +1,449,214 +701%
RSCM
21
Rock Springs Capital Management
Maryland
$7.26M +$270K +57,086 +4%
SCM
22
Soleus Capital Management
Connecticut
$5.93M -$1.4M -295,202 -19%
PHP
23
Parkman Healthcare Partners
Connecticut
$5.36M -$3.34M -706,456 -38%
AG
24
Artal Group
Luxembourg
$4.71M
PCM
25
Peregrine Capital Management
Minnesota
$3.41M +$3.46M +731,048 New

APLT Hedge Fund Activity: Q2 2024 in Review

94 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q2 2024, worth a combined $482M — down 25% from $639M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new APLT positions and 24 closed out — a net gain of 6 holders — while 31 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $26.4M. The largest seller was Laurion Capital Management, cutting an estimated $6.77M.

  • 94 institutional investors held Applied Therapeutics (APLT) as of Q2 2024, up from 89 in Q1 2024.
  • Funds reported $482M of Applied Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
  • 30 funds opened new Applied Therapeutics positions in Q2 2024 and 24 closed out, a net change of +6 holders.
  • The largest Applied Therapeutics buyer in Q2 2024 was BlackRock, an estimated $26.4M added.
  • The largest Applied Therapeutics seller in Q2 2024 was Laurion Capital Management, an estimated $6.77M sold.

Based on aggregated 13F filings for Q2 2024.